Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism

The farnesoid X receptor (FXR) plays an important role in mediating the dialog between the host and gut microbiota, particularly through modulation of enterohepatic circulation of bile acids. Mounting evidence suggests that genetic ablation of Fxr in the gut or gut-restricted chemical antagonism of the FXR promotes beneficial health effects, including the prevention of nonalcoholic fatty liver disease in rodent models. However, questions remain unanswered, including whether modulation of FXR activity plays a role in shaping the gut microbiota community structure and function and what metabolic pathways of the gut microbiota contribute in an FXR-dependent manner to the host phenotype. In this report, new insights are gained into the metabolic contribution of the gut microbiota to the metabolic phenotypes, including establishing a link between FXR antagonism, bacterial bile salt hydrolase activity, and fermentation. Multiple approaches, including unique mouse models as well as metabolomics and genome-scale metabolic models, were employed to confirm these results. ABSTRACT The gut microbiota modulates obesity and associated metabolic phenotypes in part through intestinal farnesoid X receptor (FXR) signaling. Glycine-β-muricholic acid (Gly-MCA), an intestinal FXR antagonist, has been reported to prevent or reverse high-fat diet (HFD)-induced and genetic obesity, insulin resistance, and fatty liver; however, the mechanism by which these phenotypes are improved is not fully understood. The current study investigated the influence of FXR activity on the gut microbiota community structure and function and its impact on hepatic lipid metabolism. Predictions about the metabolic contribution of the gut microbiota to the host were made using 16S rRNA-based PICRUSt (phylogenetic investigation of communities by reconstruction of unobserved states), then validated using 1H nuclear magnetic resonance-based metabolomics, and results were summarized by using genome-scale metabolic models. Oral Gly-MCA administration altered the gut microbial community structure, notably reducing the ratio of Firmicutes to Bacteroidetes and its PICRUSt-predicted metabolic function, including reduced production of short-chain fatty acids (substrates for hepatic gluconeogenesis and de novo lipogenesis) in the ceca of HFD-fed mice. Metabolic improvement was intestinal FXR dependent, as revealed by the lack of changes in HFD-fed intestine-specific Fxr-null (FxrΔIE) mice treated with Gly-MCA. Integrative analyses based on genome-scale metabolic models demonstrated an important link between Lactobacillus and Clostridia bile salt hydrolase activity and bacterial fermentation. Hepatic metabolite levels after Gly-MCA treatment correlated with altered levels of gut bacterial species. In conclusion, modulation of the gut microbiota by inhibition of intestinal FXR signaling alters host liver lipid metabolism and improves obesity-related metabolic dysfunction. IMPORTANCE The farnesoid X receptor (FXR) plays an important role in mediating the dialog between the host and gut microbiota, particularly through modulation of enterohepatic circulation of bile acids. Mounting evidence suggests that genetic ablation of Fxr in the gut or gut-restricted chemical antagonism of the FXR promotes beneficial health effects, including the prevention of nonalcoholic fatty liver disease in rodent models. However, questions remain unanswered, including whether modulation of FXR activity plays a role in shaping the gut microbiota community structure and function and what metabolic pathways of the gut microbiota contribute in an FXR-dependent manner to the host phenotype. In this report, new insights are gained into the metabolic contribution of the gut microbiota to the metabolic phenotypes, including establishing a link between FXR antagonism, bacterial bile salt hydrolase activity, and fermentation. Multiple approaches, including unique mouse models as well as metabolomics and genome-scale metabolic models, were employed to confirm these results.

[1]  H. Goossens,et al.  Differences in gut microbiota composition between obese and lean children: a cross-sectional study , 2013, Gut Pathogens.

[2]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[3]  Sarah L. Westcott,et al.  Development of a Dual-Index Sequencing Strategy and Curation Pipeline for Analyzing Amplicon Sequence Data on the MiSeq Illumina Sequencing Platform , 2013, Applied and Environmental Microbiology.

[4]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[5]  E. Murphy,et al.  Targeting the Microbiota to Address Diet-Induced Obesity: A Time Dependent Challenge , 2013, PloS one.

[6]  G. Perdew,et al.  Metabolomics Reveals that Aryl Hydrocarbon Receptor Activation by Environmental Chemicals Induces Systemic Metabolic Dysfunction in Mice. , 2015, Environmental science & technology.

[7]  Simon W. Beaven,et al.  Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver , 2015, Hepatology.

[8]  A. Martí,et al.  Genes, lifestyles and obesity , 2004, International Journal of Obesity.

[9]  Bernard Henrissat,et al.  Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome , 2012, PLoS Comput. Biol..

[10]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[11]  F. Bäckhed,et al.  Microbiota-induced obesity requires farnesoid X receptor , 2016, Gut.

[12]  I. Albert,et al.  Persistent Organic Pollutants Modify Gut Microbiota–Host Metabolic Homeostasis in Mice Through Aryl Hydrocarbon Receptor Activation , 2015, Environmental health perspectives.

[13]  F. Gonzalez,et al.  Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity , 2015, Journal of hepatology.

[14]  Takuma Tsuchida,et al.  Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. , 2012, Metabolism: clinical and experimental.

[15]  F. Schütz,et al.  Hepatic glucose sensing is required to preserve β cell glucose competence. , 2013, The Journal of clinical investigation.

[16]  S. Sørensen,et al.  Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults , 2010, PloS one.

[17]  Karine Clément,et al.  Genetics of human obesity. , 2006, The Proceedings of the Nutrition Society.

[18]  M. J. Saad,et al.  Gut microbiota composition and its effects on obesity and insulin resistance , 2014, Current opinion in clinical nutrition and metabolic care.

[19]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[20]  Lee M. Kaplan,et al.  Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity , 2013, Science Translational Medicine.

[21]  R. Mahadevan,et al.  The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. , 2003, Metabolic engineering.

[22]  Jesse R. Zaneveld,et al.  Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences , 2013, Nature Biotechnology.

[23]  W. D. de Vos,et al.  Associations between the human intestinal microbiota, Lactobacillus rhamnosus GG and serum lipids indicated by integrated analysis of high-throughput profiling data , 2013, PeerJ.

[24]  I. Albert,et al.  Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. , 2015, The Journal of clinical investigation.

[25]  William H. Bisson,et al.  Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction , 2015, Nature Communications.

[26]  C. Hill,et al.  Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut , 2014, Proceedings of the National Academy of Sciences.

[27]  H. Inadera,et al.  Developmental origins of obesity and type 2 diabetes: molecular aspects and role of chemicals , 2013, Environmental Health and Preventive Medicine.

[28]  P. Vajro,et al.  Microbiota and Gut–Liver Axis: Their Influences on Obesity and Obesity-Related Liver Disease , 2013, Journal of pediatric gastroenterology and nutrition.

[29]  J. Montani,et al.  Substrate cycling between de novo lipogenesis and lipid oxidation: a thermogenic mechanism against skeletal muscle lipotoxicity and glucolipotoxicity , 2004, International Journal of Obesity.

[30]  A. Irving,et al.  New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[32]  T. Asano,et al.  Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity. , 2005, Diabetes.

[33]  A. Schwiertz,et al.  Microbiota and SCFA in Lean and Overweight Healthy Subjects , 2010, Obesity.

[34]  P. Hylemon,et al.  Bile acids and the gut microbiome , 2014, Current opinion in gastroenterology.

[35]  B. Staels,et al.  The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[36]  D. Brenner,et al.  Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.

[37]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[38]  James B. Mitchell,et al.  Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity , 2013, Nature Communications.

[39]  S. Daniels,et al.  Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, , 2003, Circulation.

[40]  Fei Li,et al.  FXR signaling in the enterohepatic system , 2013, Molecular and Cellular Endocrinology.

[41]  Barbara M. Bakker,et al.  The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism , 2013, Journal of Lipid Research.

[42]  E. Murphy,et al.  The gut microbiota and its relationship to diet and obesity , 2012, Gut microbes.

[43]  Martin Hartmann,et al.  Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.

[44]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.